Business Context and Reporting Period
This Form 8-K is a current report filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on January 6, 2014. The filing reports a specific corporate event rather than a financial reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is an event report and does not contain financial statements.
Material Changes and Events
Under Item 8.01 (Other Events), the Company announced the following:
- Clinical Study Agreement: Trovagene, Inc. and US Oncology Research entered into an agreement on January 6, 2014.
- Study Focus: The study will examine the utility of quantitative urine-based KRAS mutation detection and monitoring in pancreatic cancer patients.
- Exhibit: A press release detailing this agreement is included as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future performance, or specific risk factors beyond the standard disclaimer that the information furnished under Item 8.01 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the registrant name is Trovagene, Inc., not Cardiff Oncology, Inc.
- Review Exhibit 99.1 (Press Release) for specific details on the study design and timeline.
- Confirm the scope of the partnership with US Oncology Research.
- Note that this filing contains no financial data; refer to 10-K or 10-Q filings for financial metrics.